Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Avatrombopag (YM477) is a new oral thrombopoietin (TPO) receptor agonist, activating TPO receptor and increasing megakaryocytic proliferation/differentiation and platelet production.
説明 | Avatrombopag (YM477) is a new oral thrombopoietin (TPO) receptor agonist, activating TPO receptor and increasing megakaryocytic proliferation/differentiation and platelet production. |
ターゲット&IC50 | TPO receptor:3.3 nM (EC50) |
In vivo | Avatrombopag is treatment of thrombocytopenia in patients with CLD who are scheduled to undergo a procedure[1]. |
別名 | YM477, AKR-501, E5501 |
分子量 | 649.65 |
分子式 | C29H34Cl2N6O3S2 |
CAS No. | 570406-98-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: < 1mg/ml (insoluble)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Avatrombopag 570406-98-3 Immunology/Inflammation Proteases/Proteasome Thrombin Thrombopoietin Receptor megakaryocytopoiesis NOD/SCID mimic inhibit TPO E 5501 megakaryocytes YM-477 E-5501 YM477 AKR-501 phosphorylation AKR501 Inhibitor AKR 501 E5501 proliferation YM 477 inhibitor